







BMJ Open Predictors of outcome in sciatica patients following an epidural steroid injection: the POiSE prospective observational cohort study protocol

Siobhan Stynes ^{1,2}, Kym IE Snell ³, Richard D Riley ³, Kika Konstantinou ^{1,2}, Andrea Cherrington,¹ Noor Daud,¹ Raymond Ostelo ^{4,5}, John O'Dowd,⁶ Nadine E Foster ^{1,7}

To cite: Stynes S, Snell KIE, Riley RD, *et al*. Predictors of outcome in sciatica patients following an epidural steroid injection: the POiSE prospective observational cohort study protocol. *BMJ Open* 2023;**13**:e077776. doi:10.1136/bmjopen-2023-077776

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-077776>).

Received 14 July 2023
Accepted 17 October 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Siobhan Stynes;
s.stynes@keele.ac.uk

ABSTRACT

Introduction Sciatica can be very painful and, in most cases, is due to pressure on a spinal nerve root from a disc herniation with associated inflammation. For some patients, the pain persists, and one management option is a spinal epidural steroid injection (ESI). The aim of an ESI is to relieve leg pain, improve function and reduce the need for surgery. ESIs work well in some patients but not in others, but we cannot identify these patient subgroups currently. This study aims to identify factors, including patient characteristics, clinical examination and imaging findings, that help in predicting who does well and who does not after an ESI. The overall objective is to develop a prognostic model to support individualised patient and clinical decision-making regarding ESI.

Methods POiSE is a prospective cohort study of 439 patients with sciatica referred by their clinician for an ESI. Participants will receive weekly text messages until 12 weeks following their ESI and then again at 24 weeks following their ESI to collect data on leg pain severity. Questionnaires will be sent to participants at baseline, 6, 12 and 24 weeks after their ESI to collect data on pain, disability, recovery and additional interventions. The prognosis for the cohort will be described. The primary outcome measure for the prognostic model is leg pain at 6 weeks. Prognostic models will also be developed for secondary outcomes of disability and recovery at 6 weeks and additional interventions at 24 weeks following ESI. Statistical analyses will include multivariable linear and logistic regression with mixed effects model.

Ethics and dissemination The POiSE study has received ethical approval (South Central Berkshire B Research Ethics Committee 21/SC/0257). Dissemination will be guided by our patient and public engagement group and will include scientific publications, conference presentations and social media.

INTRODUCTION

Sciatica is a common variation of low back pain (LBP), usually presenting as sharp, shooting pain in the leg, often with numbness and muscle weakness.¹ In most cases, sciatica is caused by a lumbar disc herniation

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This large prospective cohort study will deliver new knowledge about the prognosis of patients with sciatica who are eligible for an ESI.
- ⇒ The study will provide better evidence about factors that can be routinely collected in clinical practice to predict the outcome of patients following their ESI.
- ⇒ This will support future evidence-based decision-making for patients and clinicians considering ESI as an intervention.
- ⇒ Patient recruitment will be challenging to achieve the target sample size, given the current demands on clinicians' time to identify eligible patients and public health service waiting lists for interventions. This may lead to selection bias.
- ⇒ The chosen predictors of outcome are based on data that can be collected in routine clinical care and do not include more costly measurements, such as biomarkers.

compressing the lumbar spinal nerve root(s), with associated inflammation.² Many patients improve, but around 30% continue to suffer from pain and related disability after 1 year.^{3,4} Sciatica is a costly health problem. A Dutch study estimated sciatica-related societal costs to account for 13% of all LBP-related costs.⁵ This translates to £268 million per year in the UK.⁶

Guidelines recommend epidural steroid injections (ESIs) for treating severe disc-related sciatica pain based on trial data that show modest benefits in terms of leg pain reduction and avoidance of surgery.⁷⁻¹⁰ ESIs can be performed in several ways (caudal, interlaminar and transforaminal approaches) and with or without imaging to verify delivery of the injectate substance to the target level in the spine.⁸ The term epidural steroid injection (ESI) is used throughout this paper to describe any type of spinal injection

(including local anaesthetic and corticosteroid) used for disc-related sciatica for reducing leg pain.

There appears to be wide variation in response to ESIs, with some patients improving to such a degree that spinal surgery is avoided, while others do not improve.^{7 11–14} Little is known about which factors predict the outcome from ESIs: patient characteristics, clinical assessment findings, imaging findings or other test results. Anecdotally, we know clinicians use the “flip of a coin” analogy, that is, explaining to patients that they have a “50:50” chance of improvement from an ESI. A recent randomised controlled trial compared surgical microdiscectomy with TFESI (transforaminal ESI) in patients with disc-related sciatica pain with symptom duration of up to 12 months.¹⁵ No significant difference was found for pain or disability outcomes, and the trial team recommended that TFESI should be considered as a first invasive treatment option. With the need to reduce low-value healthcare,¹⁶ it would be helpful to be able to better identify patients who have a reasonable chance of benefiting from ESI. This would prevent unnecessary burden on healthcare services and unnecessary healthcare costs because patients who do not improve with ESI may undergo repeat injections or experience delays in proceeding to surgery.

Our recent systematic review investigated factors that might predict outcomes following ESI in patients with disc-related sciatica that can be routinely collected in clinical practice.¹⁷ Of 15 eligible studies exploring 42 factors, we found no consistent prognostic factor; most studies found no association between the selected factors and patient outcomes or conflicting results. The overall study quality was low, with all judged to have moderate or high risk of bias. There is a clear need for a suitably powered, low risk of bias, prospective cohort to more carefully investigate factors that predict outcome following ESI.

The overall POiSE research question is: In adults with disc-related sciatica, can we accurately predict pain and functional outcomes following ESI using patient, clinical and imaging characteristics? The overall aim is to offer patients with disc-related sciatica better information about their likelihood of improvement in leg pain following ESI. Finally, the overall objective is to develop a prognostic model to support individualised patient and clinical decision-making regarding ESI.

The objectives of the POiSE study are as follows:

Objective 1: Describe the characteristics and overall prognosis in patients with sciatica who are referred for ESI for disc-related sciatica for (1) the entire cohort, (2) those who have an ESI and (3) those who do not have the ESI.

Objective 2: Identify which variables are independent prognostic factors for leg pain at 6, 12 and 24 weeks following ESI.

Objective 3: Develop and internally validate prognostic models to predict leg pain in sciatica patients at 6 weeks following an ESI.

Objective 4: Develop and internally validate prognostic models to predict (1) physical function at 6 weeks

following ESI, (2) recovery at 6 weeks following an ESI and (3) surgery or further ESI at 24 weeks following ESI.

Objective 5: Identify clusters of patients with distinct leg pain trajectories (patterns of changes in pain over time) using weekly leg pain measures until 12 weeks and 6 months following ESI.

Objective 6: Explore if prognostic factor effects differ in those who have an ESI and those who do not.

METHODS

The POiSE study is a multi-centre, prospective observational clinical cohort study.

The study will be performed and reported according to the STROBE guidance for strengthening the reporting of observational studies in epidemiology.¹⁸ The PROGRESS framework for prognosis research will guide the design and analysis of the cohort study^{19 20} and the TRIPOD statement for transparent reporting of a multivariable prediction model for individual prognosis.²¹

Cohort study setting

This prospective cohort study will be conducted in the National Health Service (NHS) spinal services and will not interfere with or change patients' usual care. Most of these services are called spinal services (some are called interface services), where patients are assessed by specialist clinicians, further imaging (MRI scans) is arranged if needed and onwards management is planned.

Spinal services will be identified by the research team through their clinical and research networks, and data from the GIRFT (Getting It Right First Time) report²² of spinal services will be used to target sites with the highest number of ESI cases performed monthly. Sites will be approached to gauge their interest in becoming a participating site. A minimum number of 10 sites is anticipated to be involved in the study.

Study population

The study population are adults consulting in spinal services with disc-related sciatica. Patients are considered eligible for the study if their clinician considers them appropriate for a referral for an ESI for their sciatica (leg pain) symptoms as part of their routine clinical care and local sciatica management pathways.

Inclusion and exclusion criteria

Patients who meet the following criteria are eligible to take part:

- ▶ Age 18 years and over.
- ▶ Clinical diagnosis of disc-related sciatica, with concordant MRI findings.
- ▶ Patient considered by assessing clinician as eligible for a therapeutic ESI as a treatment option.
- ▶ Patient has access to a mobile phone and is willing to receive/send text messages for data collection

Patients who meet the following exclusion criteria are unable to take part:

- ▶ Patients who are being offered an ESI for diagnostic purposes only.
- ▶ Patient with symptoms of neurogenic claudication due to spinal stenosis.
- ▶ Patient unable to provide full informed consent.
- ▶ Patient unable to read/write English as they would be unable to complete data collection.
- ▶ Currently pregnant as ESI not routinely offered during pregnancy.

Identification of patients for the cohort study

The staff trained in the study procedures will inform potentially eligible patients about the study and ask the patient for consent to have their contact details sent to the research study team so they can receive further information about the study. Patient details will be recorded on an online Consent to Contact (CtoC) survey sent directly to the research study team who will distribute the study pack via email or by post, depending on the patient's preference. Patients can be identified at routine clinical appointments when they are referred for the ESI or from screening waiting lists of patients listed for an ESI on sites with waiting lists for injections. If the patient is not interested in the study, their year of birth and sex will be completed in the online form to record basic demographics of all invited patients. If the patient returns the completed consent form and baseline questionnaire to the research team, they become a participant in the study.

Data collection

Data collection will be from questionnaires, case report forms (CRFs), text messages, MRI scans and hospital records.

Primary outcome measure

The primary outcome measure for the prognostic model is leg pain intensity (Numerical Rating Scale (NRS) of 0–10). The primary time point is 6 weeks following the ESI. The leg pain intensity measure will be collected via weekly text messages and follow-up questionnaires using the question, 'In the last week, on average, how intense was your usual sciatica leg pain rated on a 0–10 scale, where 0 is "no pain" and 10 is "pain as bad as could be"?'²³

Secondary outcome measures

The secondary outcome measures for describing the overall prognosis and developing prognostic models are

- ▶ leg pain intensity (NRS 0–10).
- ▶ Physical function limitations (Oswestry Disability Index (ODI) 0–100)²⁴ collected via online and postal questionnaires.
- ▶ Patient-reported recovery collected via online and postal questionnaires using a six-point ordinal scale from 'completely recovered' to 'much worse', where symptoms resolution is defined as a response of either 'completely recovered', 'much better' or 'better'.²⁵
- ▶ Undergone, or listed for surgery for sciatica, or further ESI. These data will be captured in patient-completed

questionnaires or hospital notes review at 24 weeks following ESI.

Baseline descriptive variables

The following descriptive variables will be collected at baseline and detailed in [table 1](#).

Age at time of baseline questionnaire completion, sex of participant, current smoking status, height and weight to calculate BMI using the formula mass (kg)/height (m²). BMI categories will be defined according to BMI score ranges as normal/underweight (<25), overweight (25 to <30) or obese/morbidly obese (30 to >40). Socio-economic status will be determined based on the participant's current or most recent paid job. The Standard Occupational Classification system will be used to categorise job titles into four levels: Managerial and professional occupations (higher), intermediate occupations (intermediate), routine and manual occupations (routine), never worked and long-term unemployed.²⁶

Back pain intensity (NRS 0–10) will be asked in the same manner as the leg pain intensity question: In the last week, on average, how intense was your usual back pain rated on a 0–10 scale, where 0 is 'no pain' and 10 is 'pain as bad as could be'. Duration of symptoms (months) will be established from the question. 'How long have you had this current bout/episode of sciatica leg pain'? With 13 tick options ranging from '1 month' up to 'more than 12 months'.

Work-related variables will be included for the proportion of employed patients with time off work due to sciatica. Two questions will be asked: 'Have you self-certified time off work because of your current bout/episode of sciatica leg pain?' and 'Have you been given any "sick notes" or "fit notes" from your doctor because of your current bout/episode of sciatica leg pain? Time off work in the last month (days) due to sciatica will be asked. Interference of pain with work performance will be measured on a 0 to 10 scale, where 0 is "not at all" and 10 is "the pain is so bad I am unable to do my job"'.²⁷

Anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS), scored from 0 (no anxiety or depression) to 21 (high level of anxiety or depression).²⁷ Comorbidities will be recorded from a list of five conditions (chest problems, heart problems, hypertension, diabetes, circulation problems in legs). Sleep disturbance due to sciatica symptoms will be asked (Jenkins sleep questionnaire).²⁸ General health will be measured by asking patients to rate their health as either good/very good/excellent, fair or poor.

Self-reported resource use in the last 6–12 weeks related to their sciatica will be obtained on primary care consultations (general practitioners, practice nurses, other primary care practitioner), secondary care consultations (eg, Emergency Department, hospital consultants and physiotherapists), private care consultations (eg, physiotherapists, chiropractors, osteopaths and consultants) prescriptions, hospital-based procedures (diagnostic tests, injections, and investigations) and surgery.

Table 1 Predictor variables collected at baseline

Condition specific factors	Response to treatment for previous episodes Previous history of lumbar spine surgery Duration of current sciatica symptoms Treatment expectations
Work items	Litigation (ongoing claim/secondary gain), Off work due to sciatica symptoms
Medication	Long-term opioid medication use (ie, for >3 months)
Physical function	Physical function measure
Psychological	Pain catastrophising Self-efficacy Anxiety Depression Distress and somatisation Fear avoidance beliefs
Pain	Leg pain greater than back pain Presence of neuropathic pain features Sleep disturbed due to sciatica symptoms Number of additional pain sites in the body Constant or intermittent leg pain Bilateral leg symptoms.
Clinical assessment	Positive Straight Leg Raise (SLR) test Leg pain distribution
MRI findings	Grade of nerve root compression Associated spinal stenosis/degenerative changes (at the segment affected by the herniation) Type of disc herniation
Injection items	Type of injection (eg, transforaminal ESI and caudal ESI)

Medications for sciatica symptoms will be recorded, including analgesics, NSAIDs, opiates, gabapentin, pregabalin and amitriptyline.^{29 30} The EQ5D-5L will capture health-related quality of life.³¹

Predictor variables

The potential predictor variables (table 1) have been chosen based on the results of an expert consensus study using Delphi methodology (Stynes et al. 2023, in preparation). They will be measured by (1) questions in the baseline questionnaire, (2) items from history and physical clinical assessment collected in the CRF completed by the clinician before the ESI and (3) MRI imaging findings reported before the ESI.

Follow-up variables

In addition to the secondary outcomes for the prognostic models, the following variables will be collected in the 6-week, 12-week and 24-week questionnaires (12 weeks, 18 weeks and 30 weeks for participants who decline ESI referral) to describe the clinical course of the cohort; NRS scores for back and leg pain, sleep disturbance, anxiety and depression, days lost from work in the last month due to sciatica, pain medication and additional healthcare use. See table 2 for data collection from questionnaires.

Text message data

Text messages will be initiated once the patient consents to participate in the cohort study. Weekly text messages asking about leg pain intensity will continue every 7 days after their

first text until 12 weeks after the scheduled ESI, and a final text message will be sent at 24 weeks after the ESI. The weekly text message will also ask the participant to contact the study team with the date of their scheduled ESI, if known; this message will stop after the scheduled date of the ESI. Participants who do not respond to their text message will receive a reminder message 48 hours later.

MRI scan findings

A consultant radiologist will report the MRI scans of all participants in a standardised approach. The report will only include the MRI potential predictors agreed following the consensus study. The data recorded will include the type of disc herniation (eg, protrusion and extrusion), and associated spinal stenosis/degenerative changes at the segment affected by the herniation and the grade (severity) of nerve root compression. Arrangements will be made with participating sites to transfer the anonymised MRI images to the site handling the MRI images either electronically or post images on a compact disc. The images will be pseudo-anonymised to only include the participant study ID number so their POiSE scan report can be linked with the questionnaire, CRF and pain data.

Data analysis plan

Sample size/power calculation

The target sample size for the ESI prognostic model is 351 participants, with data for the primary outcome (leg pain intensity) at 6 weeks. As some participants may withdraw

Table 2 POiSE data collection from questionnaire schedule

Description	Measure	Baseline	6 weeks*	12 weeks*	24 weeks*
Primary Outcome measure					
Leg pain intensity	In the last week, on average, how intense was your usual sciatica leg pain rated on a 0–10 scale, where 0 is 'no pain' and 10 is 'pain as bad as could be'	✓	✓	✓	✓
Secondary Outcome measures					
Recovery	Single-item question		✓	✓	✓
Physical Function	Oswestry Disability index ten items scored 0 to 5 and can be converted to a percentage. Higher scores indicate higher disability level	✓	✓	✓	✓
Proceed to surgery or second injection	Two single-item questions	x	✓	✓	✓
Sociodemographics					
Age	Date of birth	✓			
Sex at birth	Male/Female	✓			
Smoking status	Two single-item questions	✓			
Socio-economic status	Current or most recent paid job	✓			
Sciatica pain characteristics					
Duration of sciatica symptoms	How long (months) have you had this current bout/episode of sciatica leg pain?	✓			
History of previous episodes	Single-item question	✓			
Constant or intermittent pain	Single-item question	✓			
Back pain intensity	In the last week, on average, how intense was your usual back pain rated on a 0–10 scale, where 0 is 'no pain' and 10 is 'pain as bad as could be'	✓	✓	✓	✓
Sleep	Jenkins sleep questionnaire	✓	✓	✓	✓
Presence of Neuropathic pain features	Two single-item questions	✓			
Leg pain distribution	Full body manikin	✓			
Number of additional pain sites	Full body manikin	✓			
Comorbidities and lifestyle					
Height and weight (BMI)	Self-reported	✓			
Comorbidities	Self-reported, pre-defined list	✓			
General health	Single-item question	✓			
Health-related quality of life	EQ5D-5L	✓	✓	✓	✓
Analgesic use	Over the counter and prescribed	✓	✓	✓	✓
Work related factors					
Current work situation	Single-item question	✓	✓	✓	✓
Time off work	Two single-item questions	✓	✓	✓	✓
Work absence	Number of days off work in the past month (days)	✓	✓	✓	✓
Work performance	0–10 NRS scale where 0=not at all affected, 10=pain is so bad that unable to do job.	✓	✓	✓	✓
Litigation	Single-item question	✓			

Continued



Table 2 Continued

Description	Measure	Baseline	6 weeks*	12 weeks*	24 weeks*
Psychosocial and behavioural factors					
Anxiety and Depression	Hospital Anxiety and Depression Scale (HADS) scored from 0 (no anxiety and depression) to 21 (high levels of anxiety and depression)	✓	✓	✓	✓
Self-Efficacy	How confident have you felt this week about managing your sciatica pain? (0=not at all, 10=extremely confident)	✓			
Fear of movement	Two single-item questions	✓			
Pain Catastrophising	Single-item question	✓			
Treatment expectations	How confident are you that the treatment you are receiving will help your sciatica leg pain? (0=not at all confident, 10=extremely confident)	✓			
Distress	Over the last 2 weeks, on average, how much distress have you been experiencing because of your sciatica leg pain? 0–10 no distress–extreme distress.	✓			
Healthcare use					
Additional healthcare use	Self-report: consultations with healthcare professionals, prescriptions and procedures (further ESI and surgery)	✓	✓	✓	✓

*Questionnaire data collection schedule for patients who decline ESI will be 12 weeks, 18 weeks and 30 weeks after baseline.

or be lost to follow-up, we aim to recruit 439 participants to ensure 351 with data for the primary outcome. The sample size ensures precise parameter estimates and reduces the potential for overfitting in model development, based on the criteria by Riley *et al.*³² This suggests that a minimum of 351 participants are needed to allow us to examine up to 25 prognostic factor parameters (and thus 14 participants per parameter) for model inclusion. This ensures a precise estimate of the model intercept and (assuming the model R^2 of at least 30%) small overfitting (eg, small difference of <0.05 in the apparent and adjusted R^2 , and target shrinkage factor of about 0.9).³³

In terms of prognostic factor effect sizes, when considering a binary factor with a 10% prevalence in one of the two categories, 191 participants are required to detect an unadjusted mean difference in pain score of 1.0 point between groups (those reporting they are improved vs not improved after ESI) with 80% power and a 5% two-tailed significance level, assuming a SD of 1.5 points for pain intensity scores.³⁴ The intended sample size is more than 150 greater than the required 191, which will allow adjustment for multiple testing and correlation among factors via a variance inflation factor.³⁵

Overall prognosis (objective 1)

We intend to summarise the overall prognosis of the entire cohort as well as those groups of participants who receive an ESI and those that do not (although we expect the latter to be a smaller group of participants). Leg pain

intensity, disability and recovery will be summarised at the different follow-up time-points to represent short-, medium- and long-term prognoses. Frequencies and percentages of missing outcomes will be summarised for each time-point. The main analysis will summarise the available outcome data for the time-points of interest (ignoring missing values). If the proportion of missing values is large, then a sensitivity analysis is conducted using multiple imputation in which missing outcomes will be imputed using outcome values from the other time-points. The frequency of missing responses will be considered, for example, a single missing response for a participant who otherwise responded regularly versus no responses for a participant beyond a certain time-point, which may signify the individual withdrawing from the study without contacting the research team to inform them of their withdrawal from the research.

Prognostic factors (primary objective 2)

To determine prognostic factors associated with the primary outcome (leg pain intensity) at the three time-points (6, 12 and 24 weeks), multivariable linear regression will be used to investigate the associations between potential prognostic factors and leg pain in the ESI group. The independent prognostic value of each factor will be evaluated after accounting for all other potential prognostic factors by including them all in the multivariable model. In addition, the variables 'type of injection' (eg, caudal or transforaminal epidural) and 'duration of

symptoms up to time of injection' will be included in the model, as well as 'baseline leg pain intensity score'. Non-linear associations will be explored for continuous factors using multivariable fractional polynomials (thus avoiding categorisation).

Prognostic models for primary outcome (primary objective 3)

A predefined set of prognostic factors (corresponding to up to 25 parameters) will be considered for inclusion in a multivariable linear regression model to predict leg pain intensity outcome at 6 weeks following ESI. The model will be developed using backwards elimination and a p value for exclusion of 0.157 (corresponding to a selection based on Akaike's Information Criteria).³⁶ Factors that reached consensus as to their potential role in predicting outcome following ESI from the Delphi study will be retained in the model regardless of statistical significance, including baseline leg pain intensity. For comparison, a full model (with all variables included) will also be estimated.³³ Fractional polynomials will be considered for modelling non-linear continuous variables using multivariable fractional polynomial modelling.³⁷ This procedure performs a series of tests for each continuous variable to compare more complex non-linear functions (using a second-degree fractional polynomial function FP2) with simpler non-linear functions (using a first-degree fractional polynomial function, FP1) and a linear function.

Internal validation

Apparent model performance will be quantified using the R^2 statistic and calibration plots (and associated measures such as calibration slope and calibration-in-the-large) estimated in the model development dataset.³³ Optimism due to potential overfitting will then be checked and adjusted for using an internal validation approach via bootstrapping. We will obtain 1000 bootstrap samples (each the same size as the original dataset) by sampling (with replacement) individuals from the original dataset. Then, to examine potential overfitting and produce optimism-adjusted performance estimates, in each bootstrap sample, a new model will be produced using the same process (eg, backwards selection) as above, and the model's predictive performance is then evaluated on the original sample. The average difference in the bootstrap models' apparent performance (in the bootstrap sample) and the test performance (in the original dataset) provide optimism for each performance measure. Optimism-adjusted estimates of performance will then be derived by subtracting the optimism estimates from the original apparent performance estimates for the original model. Finally, shrinkage will be applied to correct for overfitting by multiplying the original model's beta regression coefficients (predictor effects in the original model) by a uniform shrinkage factor (equal to the optimism-adjusted calibration slope) and by then re-estimating the intercept to ensure overall calibration-in-the-large while constraining the revised predictor effects at their shrunken value.³³ This will give the final model.

Regression coefficients, along with standard errors and 95% CI, will be reported for the original (preshrinkage) model. Regression coefficients alone will be reported for the final shrunken model. Performance measures will be reported with 95% CI for the apparent performance, as well as estimates of optimism-corrected performance from the internal validation.

For comparison, a full model forcing in all candidate prognostic factors will be produced to avoid backwards selection, with otherwise the same process of model development and internal validation as described above. Also, a model developed using a multivariate linear regression accounting for the correlation of outcome values at 6, 12 and 24 weeks will be considered.

Prognostic models for secondary outcomes (objective 4)

Model development for physical function at 6 weeks will follow the same strategy as for the primary outcome of leg pain intensity described above. For recovery at 6 weeks and surgery or further ESI at 24 weeks, which are both binary outcomes, logistic regression models will be used instead of linear regression models. For these two logistic models, discrimination will be assessed (using the C-statistic) in addition to calculating measures of calibration, and clinical utility will be assessed using net benefit and decision curves, with the range of important risk thresholds predefined based on consultation with clinicians and patients.

Missing data

Missing data will be summarised as frequencies and proportions for each variable. Multiple imputations will be used to handle missing data, using multivariate imputation by chained equations and assuming data are missing at random. Reasons for the missing values will be explored to investigate whether the missing at random assumption is reasonable. The number of imputations will be selected to correspond to the proportion of individuals with any missing data,³⁸ and all variables considered for inclusion in the prognostic model will be included in the imputation model, as well as including the outcome variables. Rubin's rules will be used to combine estimates across imputations.³⁹

Leg pain trajectories (objective 5)

Latent class growth analysis^{40 41} will be used to identify distinct groups (clusters) of participants with similar trajectories of leg pain intensity using weekly leg pain data from text message responses. Analysis will use those with baseline plus at least two follow-up measures within the 3-month timeframe. Appropriate polynomial functional form for each trajectory will be chosen, and statistical indices used to assess model fit will include the Bayesian Information Criterion and bootstrapped likelihood ratio test. Participants will be assigned to trajectories according to the maximum probability assignment principle.⁴² Baseline patient characteristics associated with membership in each trajectory and treatment will be described.

Outcomes and prognostic factors in ESI and non-ESI subgroups (objective 6)

Some individuals decline a referral for an ESI, are referred but recover while on the waiting list, or choose to have other treatments, such as surgery. To explore whether the effects of some prognostic factors differ in individuals who have an ESI and those who do not, we will use the combined dataset of both ESI and non-ESI patients if there are sufficient participants recruited in the non-ESI pathway. A cohort of approximately 90 non-ESI participants will be large enough to explore the interaction between factors identified in the final ESI prognostic model and treatment outcomes.

A linear regression model for 6-week leg pain intensity will be fitted that includes the linear combination of predictor effects from the model derived for objective 3 as a predictor, treatment (ESI vs non-ESI) and an interaction term between the linear predictor and treatment. If this interaction is significant, further exploration of interactions between individual predictors and treatment will be undertaken. If the interaction is not significant, this would suggest they are generic predictive factors and have nothing to do with treatment (ie, treatment moderators). This will be exploratory analysis as the sample size is not powered for this analysis.

Patient and public involvement

We have adopted the approach advocated by INVOLVE Standards for Patient and Public involvement (PPIE). Patients' experiences of referral for an ESI and subsequent outcomes after ESI helped inform the research idea and study design. PPIE input has helped tailor the recruitment strategy and will be key to sharing results and brainstorming dissemination and future implementation ideas and strategies. A consensus workshop is planned with patients and clinicians to discuss the research findings and how they might progress to develop into a clinical tool. Members of the POiSE PPIE group will help interpret the study findings from a patient perspective, advising on how best to publicise the study findings to the wider public and support the design of evidence-based information materials (eg, leaflets, online tools and patient stories) for clinicians and patients to use when considering ESI as a management option for disc-related sciatica.

Ethics and dissemination

The POiSE study has received ethical approval (South Central Berkshire B Research Ethics Committee 21/SC/0257). Findings of the POiSE study will be presented at national and international conferences and published in peer-reviewed journals. Once the results of the study have been published, further dissemination will be shared with the wider public, guided by PPIE advice.

After publication of the results of the cohort study, depersonalised datasets will be available on request from primarycare.datasharing@keele.ac.uk.

Study status

Patient recruitment and follow-up is expected to continue until the end of 2024. Recruitment has started, with more than 280 patients recruited by September 2023. The study is no longer recruiting additional NHS spinal sites to identify eligible patients.

Registration details

Research Registry www.researchregistry.com: UIN: researchregistry6844

Author affiliations

¹School of Medicine, Keele University, Keele, UK

²North Staffordshire and Stoke on Trent Integrated Musculoskeletal Service, Midlands Partnership University NHS Foundation Trust, Staffordshire, UK

³College of Medical and Dental Sciences, University of Birmingham Institute of Applied Health Research, Birmingham, UK

⁴Department of Health Sciences, VU Amsterdam Faculty of Sciences, Amsterdam, The Netherlands

⁵Department of Epidemiology and Data Science, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands

⁶Hampshire Hospitals NHS Foundation Trust, Hampshire, UK

⁷STARS Education and Research Alliance, Surgical Treatment and Rehabilitation Service, The University of Queensland and Metro North Health, Brisbane, Queensland, Australia

Acknowledgements The authors would like to acknowledge the contributions of the POiSE patient and public involvement and engagement group in designing aspects of this research study protocol.

Contributors SS conceived the study. NEF, RDR, KK, RO and JO'D helped SS shape the fellowship application to secure funding for the POiSE study. SS led the design of the study with the support of her mentorship team NEF, KK, RDR, KS, RO and JO'D. RDR and KS prepared the analysis plan. ND and SS will perform the analysis, supported by KS. AC and SS are responsible for project management and coordination activities of the study and ND is contributing to data monitoring and reporting. SS prepared the draft of the manuscript which all authors critically reviewed and approved the final version.

Funding This study was funded by National Institute for Health and Care Research (NIHR300441). This report is independent research supported by Health Education England and the National Institute for Health and Care Research (HEE/ NIHR ICA Programme Clinical Lectureship, Dr Siobhan Stynes, NIHR300441). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funder had no involvement in the study design, the writing of this report or the decision to submit the paper for publication.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Siobhan Stynes <http://orcid.org/0000-0002-5117-9034>

Kym IE Snell <http://orcid.org/0000-0001-9373-6591>

Richard D Riley <http://orcid.org/0000-0001-8699-0735>

Kika Konstantinou <http://orcid.org/0000-0003-4228-9386>

Raymond Ostelo <http://orcid.org/0000-0001-7679-7210>

Nadine E Foster <http://orcid.org/0000-0003-4429-9756>

REFERENCES

- 1 Jensen RK, Kongsted A, Kjaer P, *et al.* Diagnosis and treatment of sciatica. *BMJ* 2019;367:j6273.
- 2 Stafford MA, Peng P, Hill DA. Sciatica: a review of history, epidemiology, pathogenesis, and the role of epidural steroid injection in management. *Br J Anaesth* 2007;99:461–73.
- 3 Lequin MB, Verbaan D, Jacobs WCH, *et al.* Surgery versus prolonged conservative treatment for sciatica: 5-year results of a randomised controlled trial. *BMJ Open* 2013;3:e002534.
- 4 Konstantinou K, Lewis M, Dunn KM, *et al.* Stratified care versus usual care for management of patients presenting with sciatica in primary care (scopic): a randomised controlled trial. *Lancet Rheumatol* 2020;2:e401–11.
- 5 van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of back pain in the Netherlands. *Pain* 1995;62:233–40.
- 6 Foster NE, Konstantinou K, Lewis M, *et al.* The clinical and cost-effectiveness of stratified care for patients with sciatica: the scopic randomised controlled trial protocol (ISRCTN75449581). *BMC Musculoskelet Disord* 2017;18:172.
- 7 NICE. *Low Back Pain and Sciatica in Over 16s: Assessment and Management*. London: National Institute for Health and Care Excellence: Clinical Guidelines, 2016.
- 8 NHS England. *National Low Back and Radicular Pain Pathway 2017 Together with Implementation Guide Including Implementation of NICE Guidance NG59 "Low back pain and sciatica in over 16s: assessment and management 2016"*. 2016.
- 9 Manchikanti L, Knezevic NN, Navani A, *et al.* Epidural interventions in the management of chronic spinal pain: American society of interventional pain physicians (ASIPP) comprehensive evidence-based guidelines. *Pain Physician* 2021;24:S27–208.
- 10 Lee J, Gupta S, Price C, *et al.* Low back and radicular pain: a pathway for care developed by the British pain society. *Br J Anaesth* 2013;111:112–20.
- 11 Oliveira CB, Maher CG, Ferreira ML, *et al.* Epidural corticosteroid injections for sciatica: an abridged Cochrane systematic review and meta-analysis. *Spine (Phila Pa 1976)* 2020;45:E1405–15.
- 12 de Bruijn TM, Miedema HS, de Groot IB, *et al.* Clinical relevance of epidural steroid injections on lumbosacral radicular syndrome-related symptoms. *Clin J Pain* 2021;38:149–50.
- 13 Verheijen EJA, Bonke CA, Amorij EMJ, *et al.* Epidural steroid compared to placebo injection in sciatica: a systematic review and meta-analysis. *Eur Spine J* 2021;30:3255–64.
- 14 Manchikanti L, Knezevic E, Knezevic NN, *et al.* Epidural injections for lumbar radiculopathy or sciatica: a comparative systematic review and meta-analysis of cochrane review. *Pain Physician* 2021;24:E539–54.
- 15 Wilby MJ, Best A, Wood E, *et al.* Microdiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT. *Health Technol Assess* 2021;25:1–86.
- 16 Foster NE, Anema JR, Cherklin D, *et al.* Prevention and treatment of low back pain: evidence, challenges, and promising directions. *Lancet* 2018;391:2368–83.
- 17 Nagington A, Foster NE, Snell K, *et al.* Prognostic factors associated with outcome following an epidural steroid injection for disc-related sciatica: a systematic review and narrative synthesis. *Eur Spine J* 2023;32:1029–53.
- 18 von Elm E, Altman DG, Egger M, *et al.* The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008;61:344–9.
- 19 Hemingway H, Croft P, Perel P, *et al.* Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. *BMJ* 2013;346:e5595.
- 20 Riley RD, van der Windt D, Croft P, *et al.* *Prognosis research in healthcare: Concepts, methods, and impact*. Press OU, 2019.
- 21 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162:735–6.
- 22 Getting it right first time. n.d. Available: <https://gettingitrightfirsttime.co.uk/wp-content/uploads/2019/01/Spinal-Services-Report-Mar19-L1.pdf>
- 23 Dunn KM, Jordan KP, Croft PR. Recall of medication use, self-care activities and pain intensity: a comparison of daily diaries and self-report questionnaires among low back pain patients. *Primary Health Care* 2010;11:93.
- 24 Fairbank JC, Couper J, Davies JB, *et al.* The Oswestry low back pain disability questionnaire. *Physiotherapy* 1980;66:271–3.
- 25 Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *J Man Manip Ther* 2009;17:163–70.
- 26 The National Statistics socio-economic classification (NS-SEC rebased on Soc2010). 2016b. Available: <http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/guide-method/classifications/current-standard-classifications/soc2010/soc2010-volume-3-ns-sec--rebased-on-soc2010--user-manual/index.html#6OfNSbSvtNNS-ecN-SroS>
- 27 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
- 28 Jenkins CD, Stanton BA, Niemczyk SJ, *et al.* A scale for the estimation of sleep problems in clinical research. *J Clin Epidemiol* 1988;41:313–21.
- 29 Arden NK, Price C, Reading I, *et al.* A Multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. *Rheumatology (Oxford)* 2005;44:1399–406.
- 30 Lassere MN, Johnson KR, Thom J, *et al.* Protocol of the randomised placebo controlled pilot trial of the management of acute sciatica (SCIATICA): a feasibility study. *BMJ Open* 2018;8:e020435.
- 31 Herdman M, Gudex C, Lloyd A, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727–36.
- 32 Riley RD, Snell KIE, Ensor J, *et al.* Minimum sample size for developing a multivariable prediction model: part I - continuous outcomes. *Stat Med* 2019;38:1262–75.
- 33 Harrell FE. *Regression modeling strategies, with applications to linear models, logistic regression, and survival analysis, 2nd ed.* New York: Springer, 2015.
- 34 Neter J, Wasserman W, Kutner M. *Applied Linear Regression Models*. Richard D. Irwin, Inc, 1983.
- 35 Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. *Stat Med* 2000;19:441–52.
- 36 Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. *J R Stat Soc Ser C Appl Stat* 1999;48:313–29.
- 37 Royston P, Sauerbrei W. *Multivariable model-building – A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables*. Chichester: John Wiley, 2008.
- 38 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;30:377–99.
- 39 Rubin DB. *Multiple imputation for nonresponse in surveys*. New York: Wiley, 1987.
- 40 Ogollah RO, Konstantinou K, Styne S, *et al.* Determining one-year trajectories of low-back-related leg pain in primary care patients: growth mixture modeling of a prospective cohort study. *Arthritis Care Res (Hoboken)* 2018;70:1840–8.
- 41 Tremblay RE, Nagin DS, Séguin JR, *et al.* Physical aggression during early childhood: trajectories and predictors. *Can Child Adolesc Psychiatr Rev* 2005;14:3–9.
- 42 Jung T, Wickrama KAS. An introduction to latent class growth analysis and growth mixture modeling. *Social & Personality Psych* 2008;2:302–17.